A JPMorgan analysis reported that biopharma licensing reached $82.7 billion in announced deal value in Q1 2026, while upfront cash represented only about 6% of total deal value—suggesting partners are pushing more development risk into back-end milestones. The report also showed biopharma M&A totaling $40.9 billion across 32 deals in Q1. Venture funding, by contrast, remained more constrained: biopharma venture financing totaled $6.9 billion in Q1 2026, down from $8.6 billion a year earlier, with seed and Series A drifting toward post-pandemic lows. JPMorgan characterized the funding mix as increasingly bifurcated between later-stage de-risking and earlier-stage selectivity. For public biotech valuations, this structure matters because it changes how quickly companies can finance clinical programs without relying on high-velocity venture rounds. For big pharma, it reinforces a strategy of filling pipelines via licensing and late-stage acquisitions. The practical takeaway for the sector is that capital remains available, but terms are increasingly milestone-heavy—shaping which programs can advance and how quickly companies can build late-stage evidence packages.